These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Successful treatment of severe parasomnias with paroxetine in a 12-year-old boy. Frölich Alfred Wiater Gerd Lehmkuhl J Int J Psychiatry Clin Pract; 2001; 5(3):215-8. PubMed ID: 24926757 [TBL] [Abstract][Full Text] [Related]
23. Effects of Paroxetine,a CYP2D6 Inhibitor, on the Pharmacokinetic Properties of Hydrocodone After Coadministration With a Single-entity,Once-daily, Extended-release HydrocodoneTablet. Kapil RP; Friedman K; Cipriano A; Michels G; Shet M; Mondal S; Harris SC Clin Ther; 2016 Jan; 38(1):228-9. PubMed ID: 26615894 [No Abstract] [Full Text] [Related]
25. Paroxetine (Paxil) overdose: a pediatric focus. Myers LB; Krenzelok EP Vet Hum Toxicol; 1997 Apr; 39(2):86-8. PubMed ID: 9080633 [TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and Pharmacodynamics: A Comprehensive Analysis of the Absorption, Distribution, Metabolism, and Excretion of Psychiatric Drugs. Zakaraya Z; Abu Assab M; Tamimi LN; Karameh N; Hailat M; Al-Omari L; Abu Dayyih W; Alasasfeh O; Awad M; Awad R Pharmaceuticals (Basel); 2024 Feb; 17(3):. PubMed ID: 38543065 [TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects. Hwang S; Lee DY; Cho JY; Chung JY; Jang IJ; Yu KS; Lee S Drug Des Devel Ther; 2021; 15():2375-2384. PubMed ID: 34103898 [TBL] [Abstract][Full Text] [Related]
28. New validated HPLC methodology for the determination of (-)-trans-paroxetine and its enantiomer in pharmaceutical formulations with use of ovomucoid chiral stationary phase. Lisowska-Kuźmicz M; Kantor-Boruta M; Jończyk A; Jarończyk M; Ocios-Bębenek A; Mazurek AP; Chilmonczyk Z; Jarosz M Anal Bioanal Chem; 2014 Jun; 406(15):3697-702. PubMed ID: 24408298 [TBL] [Abstract][Full Text] [Related]
29. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748 [TBL] [Abstract][Full Text] [Related]
30. Paroxetine: an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression. Nemeroff CB J Clin Psychopharmacol; 1993 Dec; 13(6 Suppl 2):10S-17S. PubMed ID: 8106649 [TBL] [Abstract][Full Text] [Related]
31. Paroxetine: a pharmacological review. Johnson AM Int Clin Psychopharmacol; 1992 Jun; 6 Suppl 4():15-24. PubMed ID: 1331230 [TBL] [Abstract][Full Text] [Related]
33. The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor. Tulloch IF; Johnson AM J Clin Psychiatry; 1992 Feb; 53 Suppl():7-12. PubMed ID: 1531829 [TBL] [Abstract][Full Text] [Related]